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Background: Fat tissue is strongly involved in BC tumorigenesis inducing insulin resis-
tance, chronic inflammation and hormonal changes. Computed tomography (CT) imaging
instead of body mass index (BMI) gives a reliable measure of skeletal muscle mass and body
fat distribution. The impact of body composition parameters (BCPs) on chemosensitivity is
still debated. We examined the associations between BCPs and tumor response to neoadju-
vant chemotherapy (NC) in patients treated for operable breast cancer (BC).
Methods: A retrospective review of BC patients treated with NC in Modena Cancer Center
between 2005 and 2017 was performed. BCPs, such as subcutaneous fat area (SFA), visceral
fat area (VFA), lumbar skeletal muscle index (LSMI) and liver-to-spleen (L/S) ratio were
calculated by Advance workstation (General Electric), software ADW server 3.2 or 4.7. BMI
and BCPs were correlated with pathological complete response (pCR) and survival
outcomes.
Results: 407 patients were included in the study: 55% with BMI < 25 and 45% with BMI
≥ 25. 137 of them had pre-treatment CT scan imagines. Overweight was significantly
associated with postmenopausal status and older age. Hormonal receptor positive BC was
more frequent in overweight patients (p<0.05). Postmenopausal women had higher VFA,
fatty liver disease and obesity compared to premenopausal patients. No association between
BMI classes and tumor response was detected. High VFA and liver steatosis were negative
predictive factors for pCR (pCR rate: 36% normal VFA vs 20% high VFA, p= 0.048; no
steatosis 32% vs steatosis 13%, p=0.056). Neither BMI classes nor BCPs significantly
influenced overall survival and relapse-free survival.
Conclusion: Visceral adiposity as well as steatosis were closely involved in chemosensi-
tivity in BC patients treated with NC. Their measures from clinically acquired CT scans
provide significant predictive information that outperform BMI value. More research is
required to evaluate the relationship among adiposity site and survival outcomes.
Keywords: BMI, fat tissue, sarcopenia, pathological complete response, breast cancer
Introduction
Obesity is a known risk factor for various health disorders, including breast cancer
(BC).1 Obesity is generally evaluated using body mass index (BMI), that is an
indirect measurement of adipose tissue, calculated as weight in kilograms divided
height in meters squared. BMI cannot account for differences in fat distribution and
cannot distinguish between adipose tissue and muscles. In fact, low BMI can mask
excess of adiposity such as high BMI can mask low muscularity. Computed
tomography (CT) imaging can be a useful tool for a direct measure of body fat
Correspondence: Claudia Omarini
Division of Medical Oncology,
Department of Medical and Surgical
Sciences for Children & Adults, University
Hospital of Modena, Via Del Pozzo 71,
Modena 41122, Italy
Tel +39 059 4222845
Email claudia.omarini@gmail.com
Cancer Management and Research Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Cancer Management and Research 2019:11 9563–9569 9563
http://doi.org/10.2147/CMAR.S216034
DovePress © 2019 Omarini et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
distribution distinguishing among visceral, subcutaneous,
internal fat tissue (mostly in the liver) and skeletal muscle
mass.2
Several studies highlighted the association between
obesity and poor prognosis in BC patients.3 It is well
known that women with BC, who are overweight or gain
weight after diagnosis, have a greater risk for recurrence
and death.3 Moreover, not only the excess of adiposity, but
also sarcopenia (low skeletal muscle mass) seems to be a
negative prognostic factor for death and recurrence in
patients with non-metastatic BC.4 Biologically, fat cells
can produce inflammatory cytokines (Il-6 and TNF-α),
growth factors (insulin growth factor receptor), aromatase
and adiponectin.5 These molecules increase the level of
leptin and endogenous sex steroids determining chronic
inflammation and insulin resistance.5 Given these facts,
adipose tissue may influence treatment sensitivity. Only
two studies, with a small sample size, have examined the
relationship between body composition and neoadjuvant
treatment sensitivity in BC women, providing controver-
sial results.6,7 Our goal was to examine associations
between measure of body composition parameters
(BCPs), considering adiposity and sarcopenia, and
response to neoadjuvant chemotherapy (NC) in patients
treated for operable BC.
Patients And Methods
Patient Population
We performed a retrospective review of the electronic
medical records of all patients treated with NC for early
BC in Modena Cancer Center between 2005 and 2017. All
the patients with a histologically proven diagnosis of BC
(stage I–III) treated with primary chemotherapy either
within clinical trials or on the basis of standard guidelines
were included. Patients needed weight and height available
and/or pre-treatment CT scan imagines. No other eligibil-
ity/exclusion criteria were applied. Tumor-specific charac-
teristics, including cancer stage, grade and tumor subtypes,
were collected. Tumor subtypes were defined as follows:
human epidermal growth factor receptor 2 (HER2) posi-
tive BC (HER2 status was reported as positive or negative
according to IHC 3+ or HIS amplification), hormone
receptor positive BC (estrogen and/or progesterone recep-
tors expression >1% and HER2 negative) and triple nega-
tive (TN) BC (hormone receptor and HER2 negative). NC
was given according to the standard recommendation, dose
reduction or drug discontinuation were applied in case of
toxicity according to clinician’s choice. Data about patient
characteristics’ such as age, menopausal status, weight and
height at the beginning of NC were collected. Responses
to NC were collected too. Pathological complete response
(pCR) was defined as complete disappearance of invasive
tumor in the breast and axillary lymph nodes.
Body Mass Index (BMI)
According to the international classification of body mass
index (BMI), patients were categorized into two main
classes: normal weight (BMI < 25) and overweight (BMI
≥ 25). Moreover, in the subgroup of normal weight
patients, women with BMI <18.5 were classified as under-
weight (BMI < 25) while overweight patients with BMI ≥
30 were considered obese.
Body Composition Parameters (BCPs)
For patients with available CT scan imagines taken at the
time of the initial treatment, BCPs were calculated by
Advance workstation (General Electric), software ADW
server 3.2 or 4.7. The cutoff points used for classifying
BCPs were based on data in the literature.6,8 Radiologists,
who performed the BCPs measures, were blinded for
clinical data. We evaluated subcutaneous fat area (SFA,
cm2), visceral fat area (VFA, cm2), lumbar muscle cross-
sectional area (LMCA, m2) and liver steatosis (L/S ratio).
In particular, the cut-off for high SFA and VFA was 100:
VFA and SFA < 100 meaning normal visceral or subcuta-
neous adiposity while VFA or SFA ≥ 100 meaning high
visceral or subcutaneous adiposity, respectively. Using
BMI and VFA value, the presence of Obesity Disease,
defined as BMI ≥ 25 and VFA ≥ 100 was evaluated too.
The lumbar muscle cross-sectional area (LMCA, m2) was
used as a measure of total body skeletal muscle mass
including psoas, paraspinal and abdominal wall muscles.
In order to adjust the LMCA according to patient stature,
we calculated the lumbar skeletal muscle index (LSMI,
cm2/m2): total L3 skeletal muscle mass/body surface area.
The cut-off value for LSMI was 38.5: patients with LSMI
< 38.5 were sarcopenic while those with LSMI ≥ 38.5
were normal. Finally, the presence of liver steatosis was
considered as a measure of internal fat distribution. The
CT liver-to-spleen ratio (L/S ratio) was used for fatty liver
analysis. Fatty liver was defined as L/S ratio <1.
Statistical Analysis
Baseline clinical characteristics were compared between
BMI subgroups (<25 vs ≥25) by chi-square test for
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categorical variables (i.e. menopausal status, BC subtypes,
grade, neoadjuvant chemotherapy, type of surgery, stage)
and by Wilcoxon Mann–Whitney test for continuous vari-
ables (i.e. age at diagnosis). The association between
BCPs and menopausal status and the association between
BCPs and pathological complete response were evaluated
through the chi-square test. The association between BCPs
and pCR was assessed by calculating odds ratio and their
95% confidence intervals through univariate logistic
regression.
Overall survival (OS: defined as the time from diag-
nosis of BC to death/last follow-up), and relapse-free
survival (RFS: defined as the time from the date of the
diagnosis to the date of the first documented relapse or
death) were assessed. Hazard ratios (HRs) and their 95%
confidence intervals (CIs) were obtained through univari-
ate and multivariate Cox models considering BMI sub-
groups, BCPs and pathological complete response.
All analyses were performed using STATA 14
(StataCorp. 2015. Stata Statistical Software: Release 14.
College Station, TX: StataCorp LP).
Results
A total of 407 patients were included in the study, 137
of them had pre-treatment CT scan imagine available for
BCPs analysis (Figure 1). Overall, 225 were normal
weight with a BMI score under 25 compared to 182
(45%) overweight. Specifically, in the subgroup of over-
weight women 37% (68) were obese. Only 8 patients
were underweight. Patient, tumor and treatment charac-
teristics stratified by BMI subgroups are listed in
Table 1. The two cohorts of patients were well balanced
according to treatment administered, type of surgery,
grade and stage of disease. There was no association
between clinical stage, nuclear grade, neoadjuvant che-
motherapy regimen, type of surgery and BMI subgroups
(p=not significant). Overall, 75% of patients received
anthracycline-taxane-based regimen, 5% taxane-based
chemotherapy, 9% anthracycline-based regimen and 8%
platinum-based regimen. Of note, 7% of overweight
patients received a chemotherapy dose reduction due to
their high body surface area. Considering patients’ char-
acteristics, overweight was significantly associated with
postmenopausal status and older (≥65 years) age.
Particularly, 37% of premenopausal women were over-
weight vs 53% of postmenopausal women (Table 1).
Considering tumour subtypes and BMI, hormonal recep-
tor positive (HR+) tumors were more frequent in over-
weight women (p<0.05). Regarding BCPs, most of the
patients (94%) had high SFA while VFA was normal in
most than half of them. Overall, 34% of women had
criteria for Obesity Disease. Moreover, liver steatosis
was detected in 18% of women. Finally, 48 patients
were sarcopenic, 8 of them with sarcopenic overweight.
We found no detectable difference between body fat
distribution parameters and tumor subtype. On the con-
trary, postmenopausal status was significantly associated
with high VFA, fatty liver disease and obesity (Table 2).
Overall, 25% of patients achieved pCR. In particular,
57% of them (59 patients) were normal/underweight vs
43% (44) overweight according to BMI classification
(p=not significant) (Table 1). On the contrary, high visceral
fat and liver steatosis were negative predictive factors for
tumor response to neoadjuvant chemotherapy (p≤0.05)
(Table 3 – Figure 2). In particular, in the subgroup of
patients with pCR, 67% had normal visceral fat and 92%
absence of fatty liver disease, respectively. No statistical
significant correlation between BCPs and pCR according
to BC phenotype was detected.
At the time of the analysis, 25 patients (6%) had died
and 33 (8%) had experienced a recurrence: 7 (3.8%) and
12 (6.5%) in overweight subgroup vs 18 (8%) and 21 (9%)
in normal weight cohort, respectively. Neither BMI classes
nor BCPs distribution significantly influenced overall sur-
vival and relapse-free survival. Only pCR was signifi-
cantly associated with better survival outcomes in
univariate analysis. As expected, patients with pCR have
better OS (HR 0.37; 95% CI, 0.18 to 0.77, p= 0.008) and
RFS (HR, 0.34; 95% CI, 0.16 to 0.74, p= 0.007) compared
to patients with residual cancer disease after systemic
therapy.Figure 1 Flowchart of the study population.
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Discussion
The achievement of pCR is a known prognostic factor in BC
patients treated with NC. Several biological and clinical para-
meters influence tumor response to chemotherapy.9–11 Body
fat tissue seems to be one of these factors. Fat tissue promotes
cancer progression by increasing cell proliferation, cell survi-
val and metastatic processes.5 Adipose tissue determines a
dysregulation of several metabolic pathways by a continuous
crosstalk between fat tissue and cancer cells.12 Adipocytes
modify tumor microenvironment inducing insulin resistance
and inflammation by the production of leptin, adiponectin,
plasminogen activator inhibitor-1 and vascular endothelial
growth factor.13 In particular, finding from a recent clinical
studies review, suggested how the influence of adipose tissue
on cancer development depends on the type of fat too. Visceral
adipose tissue seems to be more bio-energetically active and
with more pro-cancer activity than subcutaneous adipose
tissue.14 CT scan imagines are a useful tool to assess informa-
tion on body fat distribution and muscle mass. In literature,
limited data exist regarding body composition and chemosen-
sitivity. Our results suggest a negative predictive role of visc-
eral fat in tumor response to NC. In particular, the presence of
visceral fat and internal fat tissue assessed from CT scan
imagines is significantly associated with lower rate of pCR.
In the subgroup of patients with pCR, 67% had normal visc-
eral fat and 92% absence of fatty liver disease, respectively.
Table 1 Patient And Clinical Characteristics By BMI Value Among Women Treated With Neoadjuvant Chemotherapy
Clinical Characteristics All Patients BMI < 25 kg/m2 BMI ≥ 25 kg/m2 p Value
Patients 407 225 (55%) 182 (45%)
n % n % n %
Age, median (range) 50 (25–80) 47 (25–80) 54 (29–80) <0.0001
Menopausal status
Premenopause 209 52 133 59 77 42 0.001
Postmenopause 198 48 92 41 105 58
BC subtypes
HR+ 155 38 75 33 80 44 0.052
HER2+ 148 36 84 37 64 35
TN 104 26 66 30 38 21
Grading
1–2 43 11 24 11 19 10 0.941
3 364 89 201 89 163 90
Neoadjuvant chemotherapy
Anthracycline 34 9 17 7 17 9 0.088
Anthracycline + taxane 307 76 171 76 136 75
Taxane 19 5 6 3 13 7
Platinum-based regimen 26 8 18 8 8 5
Other 19 5 13 6 6 3
Unknown 2 1 0 0 2 1
Type of surgery
Mastectomy 208 51 117 52 91 50 0.688
Lumpectomy 199 49 108 48 91 50
Stage
I 4 1 3 2 1 <1 0.333
II 295 73 168 74 127 70
III 108 26 54 24 54 30
pCR
Yes 103 25 59 26 44 24 0.637
No 304 75 166 74 138 76
Note: Significant P-value is shown in bold.
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No association between subcutaneous fat and tumor response
was found confirming that visceral fat tissue plays a more
central role in chemo-resistance than other type of body fat.
These evidences justify the absence of correlation between
Table 2 Body Composition Parameters In Overall Population And According To Menopausal Status
Body Composition Parameters All Patients Premenopause Postmenopause P Value
Patients 137 66 71
N % n % n %
SFA (cm2)
normal 8 6 5 8 3 4 0.403
high 129 94 61 92 68 96
VFA (cm2)
normal 73 53 52 79 21 30 <0.0001
high 64 47 14 21 50 70
LMCA (cm2/m2)
sarcopenia 48 36 25 45 23 43 0.828
normal 62 46 31 55 31 57
unknown LMCA 27 18 10 17
liver/spleen ratio Not
fatty liver disease 24 18 6 9 18 25 0.017
normal 113 82 60 91 53 75
Obesity disease (BMI ≥ 25 & VFA ≥ 100)
no 90 66 55 83 35 49 <0.0001
yes 47 34 11 17 36 51
Note: Significant P-values are shown in bold.
Table 3 Results Of The Correlation Analyses For Body Composition Parameters And pCR Rate
Body Composition Parameters Non-pCR Patients pCR Patients p Value
Patients (n) 98 39
n % n %
SFA (cm2)
normal 6 6 2 5 0.823
high 92 94 37 95
VFA (cm2)
normal 47 48 26 67 0.048
high 51 52 13 33
LMCA(cm2/cm3)
sarcopenia 34 42 14 48 0.557
normal 47 58 15 52
unknown LMCA 27
Liver/Spleen ratio
fatty liver disease 21 21 3 8 0.056
normal 77 79 36 92
Obesity disease (BMI ≥25 and VFA ≥100)
yes 62 63 28 72 0.341
no 36 37 11 28
Note: Significant P-values are shown in bold.
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BMI measure and pCR rate found in our study, too. In fact,
BMI value does not account for differences in body composi-
tion. It is known how patients with high BMI can be sarco-
penic and how patients with normal BMI can have visceral
and intra-visceral fat deposits. In literature, data on the pre-
dictive role of BMI are extremely controversy. In a large study
conducted by MD Anderson Cancer Center, the pCR rate was
significantly lower in overweight patients compare to normal/
underweight ones.15 Although, a metanalysis based on eight
major trials found no association between BMI measure and
tumor sensitivity.16
Postmenopausal status is a known cause of changes
in body fat distribution, mainly increasing visceral fat
tissue.17,18 In our study population, postmenopausal status
was significantly associated with overweight, high VFA
and fatty liver compared to premenopausal women. Fat
tissue is rich in aromatases, enzyme able to convert andro-
gens to estrogens. It is well demonstrated that overweight
women have a higher level of estrogens compared to
normal weight patients.18 These clinical data can explain
the increased number of HR+ BC in overweight women
compared to normal weight ones founded in our analysis.
Regarding sarcopenia and pCR rate, no relationship was
found in our study. That result must be interpreted with
caution considering the small number of patients found to
be sarcopenic in our study population. Data from a retro-
spective study suggested a positive predictive and prognostic
value of sarcopenia in the subgroup of normal weight
women.7 The reason for this benefit was explained by the
relatively higher chemotherapy dose used in that subgroup of
patients. On the contrary, evidence on sarcopenia and tumor
other than BC identified a strong association between sarco-
penia, cachexia syndrome and worse survival outcomes.19
This analysis has some limitations particularly because it is
a retrospective cohort study. Other limitation was that patients
staging with CT scan included a subgroup of women with
more aggressive tumor with a higher risk of metastatic spread
compared to women staged with liver-ultrasound and chest
x-ray. This selection could justify the absence of association
between BCPs and survival outcomes. Finally, 7% of over-
weight patients received a chemotherapy dose reduction due to
their high body surface area that could be a bias in the evalua-
tion of tumor response to chemotherapy.
Conclusion
Fat tissue is strongly involved in BC tumorigenesis inducing
insulin resistance, chronic inflammation and hormonal
changes.5 In particular, visceral adipose tissue seems to have
more pro-cancer activity than other adipose tissue.14 The
evaluation of BCPs is the best way to assess the real body
composition. BMI alone cannot account for neither differences
in fat distribution nor type of body fat. Our finding confirms
the evidence that visceral fat is more involved in cancer cells
homeostasis than other adipose tissue. High levels of visceral
and intra-visceral fat significantly influence chemosensitivity.
The rate of pCR is significantly lower in patients with visceral
adiposity and steatosis. To improve efficacy of treatment is
essential to clarify the relationship among adiposity, treatment
sensitivity and survival outcomes.
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